[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognition":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,77,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100651643","establishing-normal-cognitive-test-scores-for-adults-using-a-voice-enabled-digital-testing-platform-across-the-lifespan-100651643",false,"NCT07763392","Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan","Establishment of Age-, Sex-, and Education-Stratified Normative Data for a Fully Digital Voice-Recognized Neurocognitive Testing Platform in Adults Aged 18-100 Years","Inclusion Criteria:\n\n* Adults aged 18 to 100 years at the time of enrollment.\n* Able to read, speak, and understand English sufficiently to complete all study procedures.\n* Able and willing to provide informed consent.\n* Adequate hearing, speech, and vision (with corrective devices if needed) to complete computerized voice-recognition cognitive testing.\n* Able to independently complete the digital cognitive assessment using a computer, tablet, or smartphone with internet access (or at a supervised study site if applicable).\n\nExclusion Criteria:\n\n* Known Cognitive Impairment Self-reported or previously diagnosed cognitive impairment, memory disorder, mild cognitive impairment, or dementia.\n* Neurological Disease or Brain Injury History of a neurological condition or brain injury that, in the opinion of the investigator, may adversely affect cognitive performance.\n* Psychiatric Illness Current or untreated psychiatric illness that may significantly influence cognitive testing performance.\n* Substance Use or Cognitive-Impacting Medications Current use of substances or medications known to significantly impair cognition or recent substance use that could affect test validity.\n* Sensory or Communication Limitations Inadequate English proficiency or speech, hearing, or visual impairments that would prevent valid completion of the digital cognitive assessment.\n* Functional or Medical Conditions Affecting Cognition Medical conditions or functional impairments that, in the opinion of the investigator, may interfere with accurate assessment of normal cognitive performance.\n* Investigator Discretion Any other condition or circumstance that, in the judgment of the Principal Investigator, would compromise participant safety, study compliance, or the validity of the normative dataset.",true,"ALL","18 Years","100 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","Trial weblink: https:\u002F\u002Fwww.memoryexam.com\u002Fjob\u002Fnorms\u002F\n\nParticipants enrolled in this study will complete a single-session, non-invasive, computerized cognitive assessment administered through a secure, web-based digital platform. The purpose of the study is to establish normative cognitive performance data from healthy adults aged 18-100 years and develop age-, sex-, and education-adjusted reference values for the digital assessment platform. This is an observational study and does not involve any therapeutic intervention, investigational treatment, or alteration of routine medical care.\n\nFollowing electronic informed consent, participants will complete a standardized screening questionnaire to determine eligibility. The questionnaire collects demographic information, education, English language proficiency, medical and neurological history, psychiatric history, medication use, substance use, sleep history, and self-reported cognitive concerns. Standardized mood screening instruments (PHQ-9 and GAD-7) are also administered. Individuals meeting predefined exclusion criteria that could significantly influence cognitive performance will not be included in the normative dataset.\n\nEligible participants will then complete a digital cognitive assessment battery using standardized visual and auditory instructions. The platform utilizes automated voice-recognition technology to capture spoken responses and standardized algorithms to score performance, eliminating the need for examiner scoring and ensuring consistent administration across participants. Total study participation, including consent, screening, and testing, is approximately 30 to 45 minutes.\n\nThe cognitive battery evaluates multiple cognitive domains commonly assessed during neuropsychological examinations. Language abilities are assessed through phonemic and semantic verbal fluency tasks, measuring the ability to rapidly generate words within specified categories. Confrontation naming is evaluated using digitally presented images that participants identify verbally. Learning and memory are assessed through immediate and delayed verbal recall tasks, including recognition memory measures. Attention and working memory are evaluated using forward and backward digit span tasks. Executive functioning and attention are further assessed using a brief computerized problem-solving task. Equivalent alternate versions of selected tasks may be administered to minimize practice effects while measuring the same cognitive domains. All assessments are brief, non-invasive, and completed using spoken responses.\n\nThe platform automatically records participant responses, response timing, and scoring metrics. Voice recordings are collected solely to support automated scoring and quality assurance. All electronic data are transmitted using encrypted connections and stored within HIPAA-aligned cloud infrastructure. Personally identifiable information is stored separately from cognitive performance data using unique study identification numbers, and only authorized study personnel have access to identifiable information. De-identified data will be used to generate normative reference values.\n\nA subset of approximately 100 participants may be invited to complete a second assessment 2-4 weeks after the initial visit to evaluate test-retest reliability. Participation in this follow-up assessment is voluntary.\n\nParticipants will not receive diagnostic results or individualized interpretations of their performance because the study is intended solely to establish normative reference data. If responses on the PHQ-9 suggest potential acute self-harm risk, the platform will provide crisis resources and notify the study team in accordance with the study safety procedures.\n\nThe primary outcome of the study is the development of age-, sex-, and education-adjusted normative reference values for the digital cognitive assessment platform, supporting standardized interpretation of future assessments in clinical and research settings.",[26,27,28,29,30,31,32],"Cognition","Cognition Disorders","Cognition - Other","Dementia","Alzheimer Disease","Memory","Neurocognition",[31,26,29,34,35],"Alzheimer's Disease","Normal","RECRUITING","2026-08-13",{"date":39,"type":40},"2026-08-17","ACTUAL",{"date":42,"type":40},"2026-03-23",{"date":44,"type":22},"2027-03-23",{"name":46,"class":47},"The Neurology Center of Southern California","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100642879","phase-4-effect-of-supplemental-oxygen-therapy-on-neurocognitive-performance-in-healthy-highlanders-100642879","NCT07651917","Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders","SPIRIT_1","Inclusion Criteria:\n\n* Signed written consent\n* Age \\>18\n* Kyrgyz ethnicity\n* Born, raised and living at approximately 2500 m\n* Native or fluent in Russian language\n\nExclusion Criteria:\n\n* Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.\n* Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide\n* Heavy smoking of \\>20 cigarettes per day\n* Not able to read or adhere to the study protocol",{"count":57,"type":22},50,"INTERVENTIONAL",[60],"PHASE4","Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).",[32],[64,65,66],"Hypoxia","Altitude","Supplemental oxygen therapy","NOT_YET_RECRUITING","2026-06-10",{"date":70,"type":40},"2026-06-16",{"date":72,"type":22},"2026-06-18",{"date":74,"type":22},"2026-07-31",{"name":76,"class":47},"University of Zurich",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100638789","pacu-discharge-readiness-100638789","NCT07588542","PACU Discharge Readiness","Development of Assessment Tools for Determining Outpatient Subjects' Home-Readiness After Receiving Anesthesia (Without Family or Friend to Drive Them Home)","Inclusion Criteria:\n\n* The individuals will be identified from the operating room (OR) schedule and approached in the pre-operative area (or earlier, when possible).\n* Adult patients (18 years or older) listed for surgery and a planned 23-hour admission will be eligible for enrollment in this study.\n* Subjects must be fluent in English and not have confounding sensory or neurological limitations to participation\n\nExclusion Criteria:\n\n* Members of vulnerable populations or adults unable to consent will be included in this study.\n* Subjects that do not speak English\n* Subjects with neurological limirations",{"count":21,"type":22},[86],"NA","The use of custom-created apps, neuropsychological testing, and clinical assessments will be evaluated as tools for determining the appropriateness of PACU discharge to home.",[89,32,90],"Patient Discharge","Baseline","2026-05-08",{"date":93,"type":40},"2026-05-14",{"date":95,"type":22},"2026-05-01",{"date":97,"type":22},"2032-04-01",{"name":99,"class":47},"University of Illinois at Chicago",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":48},"100624428","assessment-of-informal-support-provided-by-caregivers-at-different-stages-of-alzheimers-disease-100624428","NCT07409506","Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease","ICAD","Inclusion Criteria:\n\n* Patients from Charpennes Hospital included in the MEM-AURA cohort\n* Patients aged 60 years and older at inclusion\n* Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage\n* Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion\n* Patients accompanied by a caregiver at inclusion\n\nExclusion Criteria:\n\n* \\- Patients or caregivers who have expressed their opposition to the study\n* Patients living in institutions or nursing homes\n* Patients protected by law (under legal protection, guardianship, or conservatorship)\n\nEarly termination Criteria :\n\n\\- Patients or caregivers withdrawing their consent to participate during the study","60 Years",{"count":109,"type":22},312,"In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system.\n\nInformal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease.\n\nThe main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.",[112,32,113],"Elderly (People Aged 65 or More)","Alzheimer s Disease",[115,116,117],"informal care","cost of alzheimer's disease","caregiver","2026-02-12",{"date":120,"type":40},"2026-02-13",{"date":122,"type":40},"2025-09-09",{"date":124,"type":22},"2027-09-09",{"name":126,"class":47},"Hospices Civils de Lyon"]